$20.685
0.195[0.95%]
Last update: 12:05PM Get Real Time Here
Syndax Pharmaceuticals
(NASDAQ:SNDX)Syndax Pharmaceuticals Stock (NASDAQ:SNDX), Analyst Ratings, Price Targets, Predictions
Syndax Pharmaceuticals Inc has a consensus price target of $33, established from looking at the 41 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and JP Morgan on March 28, 2024, March 27, 2024, and March 20, 2024. With an average price target of $38.67 between HC Wainwright & Co., HC Wainwright & Co., and JP Morgan, there's an implied 86.93% upside for Syndax Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Scotiabank
Mizuho
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Syndax Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 98.21% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 98.21% | HC Wainwright & Co. | Edward White | $41 → $41 | Maintains | Buy | Get Alert |
| 03/20/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 64.37% | JP Morgan | Anupam Rama | $31 → $34 | Maintains | Overweight | Get Alert |
| 02/28/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 98.21% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 11.19% | Scotiabank | George Farmer | $36 → $23 | Downgrade | Sector Outperform → Sector Perform | Get Alert |
| 01/02/2024 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 98.21% | HC Wainwright & Co. | Edward White | → $41 | Reiterates | Buy → Buy | Get Alert |
| 12/22/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 98.21% | HC Wainwright & Co. | Edward White | $42 → $41 | Maintains | Buy | Get Alert |
| 12/22/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 117.55% | Mizuho | Mara Goldstein | → $45 | Initiates | → Buy | Get Alert |
| 10/26/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 74.04% | Stifel | Bradley Canino | $38 → $36 | Maintains | Buy | Get Alert |
| 10/25/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 40.2% | B of A Securities | Jason Zemansky | → $29 | Initiates | → Buy | Get Alert |
| 10/17/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 83.71% | JP Morgan | Anupam Rama | $36 → $38 | Maintains | Overweight | Get Alert |
| 10/11/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 45.03% | Goldman Sachs | Chris Shibutani | → $30 | Initiates | → Buy | Get Alert |
| 10/02/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 103.05% | HC Wainwright & Co. | Edward White | $38 → $42 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 59.54% | JP Morgan | Anupam Rama | $36 → $33 | Maintains | Overweight | Get Alert |
| 08/04/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 83.71% | HC Wainwright & Co. | Edward White | → $38 | Reiterates | → Buy | Get Alert |
| 07/27/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 88.54% | Scotiabank | George Farmer | → $39 | Initiates | → Sector Outperform | Get Alert |
| 07/26/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 69.2% | Citigroup | Yigal Nochomovitz | $31 → $35 | Maintains | Buy | Get Alert |
| 07/26/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 64.37% | Barclays | Peter Lawson | $31 → $34 | Maintains | Overweight | Get Alert |
| 07/25/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $20.68 | 103.05% | Guggenheim | Michael Schmidt | $40 → $42 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Syndax Pharmaceuticals (SNDX)?
The latest price target for Syndax Pharmaceuticals (NASDAQ: SNDX) was reported by HC Wainwright & Co. on March 28, 2024. The analyst firm set a price target for $41.00 expecting SNDX to rise to within 12 months (a possible 98.21% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Syndax Pharmaceuticals (SNDX)?
The latest analyst rating for Syndax Pharmaceuticals (NASDAQ: SNDX) was provided by HC Wainwright & Co., and Syndax Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Syndax Pharmaceuticals (SNDX)?
There is no last upgrade for Syndax Pharmaceuticals.
When was the last downgrade for Syndax Pharmaceuticals (SNDX)?
The last downgrade for Syndax Pharmaceuticals Inc happened on January 31, 2024 when Scotiabank changed their price target from $36 to $23 for Syndax Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Syndax Pharmaceuticals (SNDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syndax Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syndax Pharmaceuticals was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Syndax Pharmaceuticals (SNDX) correct?
While ratings are subjective and will change, the latest Syndax Pharmaceuticals (SNDX) rating was a reiterated with a price target of $0.00 to $41.00. The current price Syndax Pharmaceuticals (SNDX) is trading at is $20.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.